*The QUEST Comparative Innovation Program (CIP) tests the effectiveness of new healthcare products and technologies through the QUEST High Performing Hospitals Collaborative. These solutions show evidence of effectiveness in decreasing hospital-associated conditions. Innovations selected as part of the CIP were evaluated by clinicians and selected based on their potential to help hospitals achieve the goals of QUEST. These solutions will be tested in the real world by QUEST hospitals and measured to determine their effectiveness in improving the quality, reliability, safety, and cost effectiveness of care.
Spectra™ MRSA*
Spectra™ MRSA is a selective chromogenic medium intended for use in the detection of nasal colonization of methicillin-resistant Staphylococcus aureus (MRSA). The easy-to-use, easy-to-read format enables cost-effective MRSA testing with final results within 24 hours, seven days a week. Spectra™ MRSA is the clear choice for screening more patients on more shifts in more hospitals. And, when it comes to culture media, no brand is more trusted than Remel.
- Exceptional performance with a Positive Predictive Value of 98.1%
- Easy-to-read denim blue colonies on a white background
- Simple procedure and interpretation adaptable on all shifts
- Labor saving, cost-effective method for an economical MRSA solution
- Requires no special handling for optimal workflow 24/7
*Patent Pending
| Product Information |
Packaging |
REF |
| Spectra™ MRSA |
10/PK |
R01821 |
| |
100/PK |
R01822 |